Key facts
- This page summarizes William Guyer's Form 4 filing for CORCEPT THERAPEUTICS INC (CORT).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 05 Aug 2024, 18:56.
William Guyer - 01 Aug 2024 Form 4 Insider Report for CORCEPT THERAPEUTICS INC (CORT)
- Reporting relationship
- Chief Development Officer
- Issuer ticker
- CORT
- Reported as of
- 01 Aug 2024
- Net transaction value
- -$170,200
- SEC form
- 4
- Accepted by SEC
- 05 Aug 2024, 18:56:09 UTC
- Prior SEC filing
- 03 Jul 2024
- Next SEC filing
- 05 Sep 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Joseph Douglas Lyon, as attorney-in-fact for William Guyer.
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
William Guyer filed Form 4 for CORCEPT THERAPEUTICS INC (CORT) on 05 Aug 2024.
Change
- Previous filing in this sequence was filed on 03 Jul 2024.
- Current net transaction value: -$170,200.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CORT
transaction
Common Stock
Options Exercise
- Transaction value
- $216,500
- Shares
- +10,000
- Change %
- +166%
- Price
- $21.65
- Shares after
- 16,039
- Date
- 01 Aug 2024
- Ownership
- Direct
- Footnotes
- F1
CORT
transaction
Common Stock
Sale
- Transaction value
- $386,700
- Shares
- -10,000
- Change %
- -62%
- Price
- $38.67
- Shares after
- 6,039
- Date
- 01 Aug 2024
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CORT
transaction
Derivative
Stock option (right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -10,000
- Change %
- -2%
- Price
- $0.000000
- Shares after
- 480,000
- Date
- 01 Aug 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 10,000
- Exercise price
- $21.65
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 3 footnotes
Footnote F1
Includes 478 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023 and 609 shares underlying unvested restricted stock units granted to the Reporting Person by the Issuer on December 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
Footnote F2
The transaction was made pursuant to a 10b5-1 plan in effect at the time of this transaction.
Footnote F3
Shares subject to the stock option vested and became exercisable with respect to 25% of the shares on the first anniversary of August 16, 2021 (the "Vesting Commencement Date") with the remaining shares vesting and becoming exercisable ratably on a monthly basis over a period of 36 consecutive months thereafter until fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service.
SEC remarks
The power of attorney under which this form was signed is on file with the Commission.